Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 138.76
ARWR's Cash to Debt is ranked higher than
73% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. ARWR: 138.76 )
ARWR' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 138.76

Equity to Asset 0.90
ARWR's Equity to Asset is ranked higher than
92% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARWR: 0.90 )
ARWR' s 10-Year Equity to Asset Range
Min: -39.56   Max: 0.95
Current: 0.9

-39.56
0.95
F-Score: 4
Z-Score: 13.71
M-Score: -2.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -23558.09
ARWR's Operating margin (%) is ranked lower than
52% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. ARWR: -23558.09 )
ARWR' s 10-Year Operating margin (%) Range
Min: -70800   Max: -40
Current: -23558.09

-70800
-40
Net-margin (%) -23292.74
ARWR's Net-margin (%) is ranked lower than
52% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. ARWR: -23292.74 )
ARWR' s 10-Year Net-margin (%) Range
Min: -33502.86   Max: 1602.7
Current: -23292.74

-33502.86
1602.7
ROE (%) -45.63
ARWR's ROE (%) is ranked higher than
67% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. ARWR: -45.63 )
ARWR' s 10-Year ROE (%) Range
Min: -225.02   Max: -28.66
Current: -45.63

-225.02
-28.66
ROA (%) -42.17
ARWR's ROA (%) is ranked higher than
64% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. ARWR: -42.17 )
ARWR' s 10-Year ROA (%) Range
Min: -447.27   Max: 705.95
Current: -42.17

-447.27
705.95
ROC (Joel Greenblatt) (%) -1966.74
ARWR's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. ARWR: -1966.74 )
ARWR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11843.37   Max: -75
Current: -1966.74

-11843.37
-75
Revenue Growth (3Y)(%) -100.00
ARWR's Revenue Growth (3Y)(%) is ranked higher than
54% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. ARWR: -100.00 )
ARWR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 63.5
Current: -100

0
63.5
EBITDA Growth (3Y)(%) -5.80
ARWR's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ARWR: -5.80 )
ARWR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56.3   Max: 190.5
Current: -5.8

-56.3
190.5
EPS Growth (3Y)(%) 1.90
ARWR's EPS Growth (3Y)(%) is ranked higher than
80% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ARWR: 1.90 )
ARWR' s 10-Year EPS Growth (3Y)(%) Range
Min: -75.1   Max: 162.1
Current: 1.9

-75.1
162.1
» ARWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ARWR Guru Trades in

Q4 2013

ARWR Guru Trades in Q4 2013

Jim Simons 54,400 sh (New)
Steven Cohen 1,500,000 sh (New)
Steven Cohen 1,883,050 sh (New)
Steven Cohen 2,000,000 sh (+33.33%)
» More
Q1 2014

ARWR Guru Trades in Q1 2014

George Soros 44,200 sh (New)
Steven Cohen 2,740,000 sh (+82.67%)
Jim Simons Sold Out
» More
Q2 2014

ARWR Guru Trades in Q2 2014

Steven Cohen 3,225,000 sh (+115.00%)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.60
ARWR's P/B is ranked higher than
85% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. ARWR: 2.60 )
ARWR' s 10-Year P/B Range
Min: 1.43   Max: 75.56
Current: 2.6

1.43
75.56
P/S 1199.63
ARWR's P/S is ranked lower than
65% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. ARWR: 1199.63 )
ARWR' s 10-Year P/S Range
Min: 0   Max: 2500
Current: 1199.63

0
2500
Current Ratio 11.49
ARWR's Current Ratio is ranked higher than
89% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ARWR: 11.49 )
ARWR' s 10-Year Current Ratio Range
Min: 0.01   Max: 302.61
Current: 11.49

0.01
302.61
Quick Ratio 11.49
ARWR's Quick Ratio is ranked higher than
90% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ARWR: 11.49 )
ARWR' s 10-Year Quick Ratio Range
Min: 0.01   Max: 302.61
Current: 11.49

0.01
302.61
Days Sales Outstanding 152.99
ARWR's Days Sales Outstanding is ranked higher than
72% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. ARWR: 152.99 )
ARWR' s 10-Year Days Sales Outstanding Range
Min: 1.12   Max: 1982.84
Current: 152.99

1.12
1982.84

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.50
ARWR's Price/Net Cash is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 109.90 vs. ARWR: 3.50 )
ARWR' s 10-Year Price/Net Cash Range
Min: 0.05   Max: 103.64
Current: 3.5

0.05
103.64
Price/Net Current Asset Value 3.50
ARWR's Price/Net Current Asset Value is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 45.70 vs. ARWR: 3.50 )
ARWR' s 10-Year Price/Net Current Asset Value Range
Min: 0.04   Max: 70.89
Current: 3.5

0.04
70.89
Price/Tangible Book 2.70
ARWR's Price/Tangible Book is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. ARWR: 2.70 )
ARWR' s 10-Year Price/Tangible Book Range
Min: 0.04   Max: 54.5
Current: 2.7

0.04
54.5
Earnings Yield (Greenblatt) -32.90
ARWR's Earnings Yield (Greenblatt) is ranked lower than
62% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. ARWR: -32.90 )
ARWR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -32.9   Max: 0
Current: -32.9

-32.9
0

Analyst Estimate

Sep15 Sep16
Revenue(Mil) 0 11
EPS($) -1.48 -1.52
EPS without NRI($) -1.48 -1.52

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. The product include ARC-520, Adipotide, CRLX-101, Tubulin Inhibitor.The drug products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the "FDCA"), and other laws within the Public Health Service Act.
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 05 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 23 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 11 2009 
Arrowhead Reports Third Quarter Fiscal 2009 Financial Results Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Apr 17 2015
Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug Apr 14 2015
Arrowhead Research (ARWR) Stock Falls Today on Jefferies Downgrade Apr 14 2015
Top Analyst Upgrades and Downgrades: Apple, AMC, BP, LendingClub, Monster, Seagate and More Apr 14 2015
Alamos Gold and Perrigo are big market movers Apr 13 2015
Arrowhead Research (ARWR) Stock Rises Today as FDA Allows Study to Proceed Apr 13 2015
Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520 Apr 13 2015
Will bulls hit target in Arrowhead? Apr 06 2015
3 Stocks Under $10 Triggering Breakout Trades Apr 02 2015
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 06 2015
ARWR: Arrowhead Acquires Novartis’ RNAi Research and Development Portfolio Mar 06 2015
Arrowhead Research Soars After Acquiring Novartis' RNAi Portfolio Mar 05 2015
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion... Mar 05 2015
Arrowhead buys Novartis' RNAi portfolio Mar 05 2015
Arrowhead Acquires Novartis’ RNAi Research and Development Portfolio Mar 05 2015
Arrowhead to Present at 2015 Barclays Global Healthcare Conference Mar 04 2015
Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1... Feb 23 2015
Latest updates on Biotechnology Companies: Special Research on Arrowhead, Bioanalytical Systems,... Feb 20 2015
Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference Feb 17 2015
ARROWHEAD RESEARCH CORP Financials Feb 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK